Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Asymmetrical (e.g., 1,2,4-triazine, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514241000 - Hetero ring is six-membered consisting of three nitrogens and three carbon atoms

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514243000 Polycyclo ring system having the hetero ring as one of the cyclos 106
Entries
DocumentTitleDate
20130045979METHOD OF TREATING MAJOR DEPRESSIVE DISORDER - The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.02-21-2013
20120172363Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers - The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). The present invention further relates to a method for preventing damage and death in mammalian organs, tissues and cells or reducing the extent of damage and death in mammalian organs, tissues and cells. In particular the invention relates to a method for the treatment, amelioration or prevention of non-neuronal and non-myocardial cell or tissue damage or death and for reducing the pain associated with non-neuronal and non-myocardial cell or tissue damage.07-05-2012
20090005383THYROID HORMONE ANALOGS - Provided herein are compounds of the formula (I):01-01-2009
20090076010DEUTERIUM-ENRICHED LAMOTRIGINE - The present application describes deuterium-enriched lamotrigine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100041660NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES - The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I):02-18-2010
20100105688PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 - The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker, wherein at least one of them is at subtherapeutic dose, as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.04-29-2010
20090264433Compounds, Compositions and Methods Comprising Triazine Derivatives - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.10-22-2009
20090012092Hiv Inhibiting 1,2,4-Triazin-6-One Derivatives - The present invention relates to HIV replication inhibitors of formula01-08-2009
20100016322Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same - Water dispersible compressed tablets and a process for preparing the same. The tablet comprising about 0.1 to 50% w/w of lamotrigine or its pharmaceutically acceptable salts, solvates, hydrates or polymorphs, about 5 to about 50% w/w of a water-soluble diluent(s), about 15 to about 70% w/w of a water swellable diluent(s), optionally one or more pharmaceutically acceptable adjuvants, wherein the ratio of water-soluble diluent(s) to water swellable diluents(s) is from about 0.6 to about 0.9 and said composition is essentially free of disintegrant, superdisintegrant and swellable clay.01-21-2010
20090042886Benzamide Inhibitors of the P2X7 Receptor - The present invention provides benzamide inhibitors of the P2X02-12-2009
20100298331TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS - The present invention relates to compounds according to formulae (IA) to (ID) and compositions that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.11-25-2010
20110301165METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1:12-08-2011
201101661422-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES - 2-Substituted isoflavonoid compounds and pharmaceutical compositions containing same are useful as anti-inflammatory agents and antioxidants and for the treatment of related diseases and conditions.07-07-2011
20100004245AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE - Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.01-07-2010
20090099189CRTH2 Receptor Ligands For Medicinal Uses - Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A04-16-2009
20080275048Substituted Diazabicycloalkane Derivates - Compounds of formula (I)11-06-2008
20080287444PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS - This invention describes novel pyrazole compounds of formula III:11-20-2008
20090030000ANTIVIRAL AGENTS - This invention relates to compounds of formula I01-29-2009
200803122384-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof - A series of mono- and binuclear 4-arylazo-3,5-diamino-pyrazoles which are useful for inhibition of cyclin-dependent kinases (preferably CDK9). Hence they can be used as antimitotic-, pro-apoptotic and antiinflammatory drugs, in particular, in chemotherapy of cancer and asthma, therapy of psoriasis and parasitoses as those caused by fungi or protists, treatment of Alzheimer's disease or as anti neurodegenerative drugs, or to suppress immunostimulation. These compounds are useful in a variety of utilities, including as intermediates in the preparation of flame-retardants, diagnostic reagents and therapeutics, including antivirals and immunosuppressors.12-18-2008
20100160328NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION - The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).06-24-2010
20110059974NOVEL RETINAMIDE RETINOIC ACID METABOLISM BLOCKING AGENTS - Retinoic acid metabolism blocking agents (RAMBAs). The RAMBAs may be used for treatment of cancer, including breast and prostate cancers. Methods for preparing novel retinamide RAMBAs. The methods include reacting RAMBAs with terminal polar carboxylic acid group with a variety of amines in the presence of suitable coupling reagents. The retinamide RAMBAs are potent inhibitors of the growth of prostate and breast cancer cells and may be useful for the treatment of these diseases in humans.03-10-2011
20110059973Pyrazole Compounds for Controlling Invertebrate Pests - The present invention relates to novel pyrazole compounds of the formulae I and II, to their salts and their N-oxides which can be used for combating or controlling invertebrate pests, in particular arthropod pests. The invention also relates to a method for controlling invertebrate pests by using these compounds. The present invention also relates to seed and to an agricultural and veterinary composition comprising said compounds.03-10-2011
20100240661AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (I) or a salt thereof:09-23-2010
20100216797PREPARATION OF THIOARABINOFURANOSYL COMPOUNDS AND USE THEREOF - Patients suffering from cancer are treated by being administered a compound represented by the following formula:08-26-2010
20100048574NOVEL HETEROCYCLIC NF-kB INHIBITORS - The present invention relates to compounds of the general formula (II):02-25-2010
20090318454NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT - Formula 1 is an antioxidant compound, wherein R, R1, or D is an antioxidant substituent; R and D are each independently selected from hydrogen or groups containing cysteine, thiols, disulfides, amino acids, amines, amides, or carboxylic acids; when one of R or D is hydrogen, the other includes a thiol, disulfide, or carboxylic acid; A is CO, SO, SO12-24-2009
20090111815Carboxamide Compound and Use of the Same - A carboxamide compound represented by the formula (I):04-30-2009
201003117551,2,4,-TRIAZIN-3,5-DIONE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The invention relates to compounds of the formula I:12-09-2010
20110118266DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS - The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R05-19-2011
20110130403PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula I: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE t e 4/PDE t e 7 inhibitors are rovided.06-02-2011
20110245251MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).10-06-2011
20110086856COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.04-14-2011
20110098303Method of promoting nail growth using thyromimetic compounds - The present invention provides methods and compositions for increasing the rate of nail growth in mammals, especially humans, using thyromimetic compounds.04-28-2011
20100004246NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS01-07-2010
20100179151TRANSDERMAL APPLICATION OF TRIAZINES FOR CONTROLLING INFECTIONS WITH COCCIDIA - The present invention relates to the transdermal application of triazines such as toltrazuril or ponazuril for controlling infections with coccidia in humans and animals.07-15-2010
20100168114INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS - Methods for determining invertebrate- and insect-specific, such as mosquito-specific, residues of acetylcholinesterases are provided herein. The methods can be used to design pesticides and insecticides that are specific for the invertebrate or insect (e.g., mosquito) enzymes, resulting in reduced toxicity concerns for mammals. Compositions for inhibiting invertebrate and insect (e.g., mosquito) acetylcholinesterases and methods for preparing the same are also provided.07-01-2010
20090176787Crystalline Forms of lamotrigine - The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.07-09-2009
20080269223Mouth Dissolvable and Meltable, and Water Dispersable Delivery Formulation - A mouth dissolvable and meltable, and water dispersable delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agents, one or more of fillers, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is spray dried mannitol, disintegrating agent is crosslinked polyvinyl pyrrolidone and binder is maltodextrin. This system optionally comprises one or more of other excipients selected from the group comprising lubricants, sweetners and flavouring agent.10-30-2008
20090291954Medical Use of Triazine Derivatives - Compounds of formula (I) especially where R11-26-2009
20110166143Heterocyclic Compounds as Pesticides - The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.07-07-2011
20120122871Oligomer-Containing Substituted Aromatic Triazine Compounds - The invention relates to (among other things) oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.05-17-2012
20120135993CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The triazine compounds are of formula (I) wherein: R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when R1 is hydrogen or ═NH when R1 is a substituent group; R3 and R4 are both carbocyclic, heterocyclic or alkyl groups and may be same or different; and R5 is hydrogen, alkyl or a cyclic aryl group, with the proviso that: when R3 and R4 are both alkyl they are linked to form a cycloalkyl group, and R5 is a cyclic aromatic group; and when R3 and R4 are both carbocyclic or heterocyclic groups, R5 is hydrogen or an alkyl group; or a salt thereof.05-31-2012
20100093737Nucleoside and Nucleotide Analogues with Quaternary Carbon Centers and Methods of Use - The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3′ position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.04-15-2010
20120135992CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS - The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula (I): in which z is a single bond or an optionally substituted linking group, R1 is a halo-alkyl group; and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system; or a salt thereof.05-31-2012
20100222351METHODS OF CONTROLLING INSECTS - The invention relates to a method of controlling insects in the family Nitidulidae using the compound 4,5-di-hydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one and also encompasses the use of compositions comprising 4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one for controlling Nitidulidae, in particular pollen beetles as well as the preparation of said compound and/or compositions for use in controlling Nitidulidae. In particular, the invention relates to the use of 4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one and/or compositions comprising this compound in controlling such insects in crops of useful plants, in particular flowering crops and/or flowering ornamental plants.09-02-2010
20100009990IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS - A compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.01-14-2010
20110212966ANTIVIRAL AGENTS - This invention relates to compounds of formula I09-01-2011
20100168113Pharmaceutical Compounds - This invention relates to novel substituted nitrocatechol derivatives, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them.07-01-2010
20110160212CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS - Provided are certain dipeptidyl peptidase inhibitors, pharmaceutical compositions thereof, and methods of use therefor.06-30-2011
20080234275METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1:09-25-2008
20110269763CRTH2 receptor ligands for medicinal uses - Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis:11-03-2011
20130096128PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS - This invention describes novel pyrazole compounds of formula III:04-18-2013
20130123263BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.05-16-2013
20130123262NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS - The present invention provides novel compounds of formula I wherein W05-16-2013
20130150368CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I:06-13-2013
20130190313ARTHROPODICIDAL ANTHRANILAMIDES - This invention provides a composition comprising a biologically effective amount of a compound of Formula 1, an N-oxide or an agriculturally suitable salt thereof07-25-2013
20120028983NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME - Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R02-02-2012
20130196999METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS - The invention relates to a method of controlling aphids that are resistant to neonicotinoid insecticides, using the compound 4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one in free form or in agrochemically acceptable salt form as well as the use of compositions comprising said compound to control neonicontinoid resistant insects. In particular the methods relate to controlling neonicotinoid resistant insects in the Aphididae family, that are resistant to one or more neonicotinoid insecticides. Methods of the invention find particular use in controlling neonicotinoid resistant insects in crops of useful plants. Furthermore, the invention extends to methods of controlling plant viruses spread by neonicotinoid resistant insects.08-01-2013
20130210823METHODS FOR CONTROLLING MITES - The present invention relates to the use of pymetrozine, and salts and compositions thereof, as a miticide, to methods and compositions comprising pymetrozine for the control of bee mites and for the reduction of bee mite infestations, such as the control and reduction of infestations of parasitic bee mites, such as 08-15-2013

Patent applications in class Asymmetrical (e.g., 1,2,4-triazine, etc.)

Patent applications in all subclasses Asymmetrical (e.g., 1,2,4-triazine, etc.)